Wonder what effect NVS will have on them, Ph3 data in second half of this year on PKC412 in FLT3+ AML. Could present a challenge to AMBI trial enrollment and future sales competition.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.